Aegerion slashes workforce; GSK president says downward pressure on drug prices is here to stay; Novartis acquires European rights to Remicade biosimilar
A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."
Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet
We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.
The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.
Prior to Medicines360's arrival on the scene, there were only three IUDs on the market. The lack of competition drove prices sky-high.
Part of drugmakers' sales growth stems from price increases; AbbVie's Venetoclax gets second Breakthrough designation; two states in India stop Avastin sales
Government pressure can influence drug-pricing decisions; Samsung's biosimilar version of Enbrel is approved in Europe; J&J to cut jobs in medical-devices business
Valeant is "uncertain" when CEO will return; Bayer hires Razorfish and iCrossing for digital; more drugmakers that sell hemophilia drugs are hiring patients
Drug pricing is easily the biggest controversy but pharma faced other issues, too, like the AMA's call to ban DTC advertising.
The firm began working with the pharma company before outrage over its drug pricing but has more recently supported the client after former CEO Martin Shkreli was arrested.
With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.
Shkreli resigns from Turing; Keytruda approved as first-line melanoma treatment; drugmakers seek to fend off California pricing ballot initiative
Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials
Physicians complain about price of Lilly's new cancer drug; AstraZeneca considers acquisition of Acerta Pharma; Shkreli plans to raise price of another old drug
UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto
Pfizer reveals Ibrance pricing strategy; AMA call for DTC ban may resonate due to pricing debate; Baxalta's Vonvendi receives FDA approval
Gleevec generic is approved; FDA issues warning on diabetes drugs; Senate will hold hearing on drug pricing
Pharma M&A expected to continue in 2016; Mylan receives government subpoena about marketing and pricing for doxycycline; KaloBios acquired rights to experimental drug to treat Chagas disease
Drug pricing has been in the spotlight since early this fall, thanks to Turing Pharmaceuticals and Martin Shkreli. One thing pharma companies can do is to communicate more proactively.
Gilead criticized over Sovaldi pricing strategy; analysis finds branded drugs cost more in the US; support is growing for Medicare negotiation of drug prices
Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.
The embroiled drugmaker now faces allegations that it violated securities law and that its staff was embedded in Philidor's day-to-day operations.
Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky
Pfizer increases the financial assistance it gives to patients; Senate committee opens investigation into drug pricing; OptumRx reportedly stopped business with Philidor a year ago
Executives at Eli Lilly, Merck and Biogen used the most recent earnings season to promote innovation and defend drug pricing.
The public said drugmakers spend too much money on marketing to doctors and patients
Three suggestions for defusing the highly charged pricing atmosphere
The FDA approves Pradaxa antidote; Valeant CEO says he expects a new pricing environment in 2016; FDA denies Shire dry-eye drug
Valeant receives subpoenas over drug pricing; BMS signs new immuno-oncology deal with Five Prime Therapeutics; Pfizer CEO says insurance coverage to blame in price debate